Tomasz Zal
Research Subjects
Tomasz Zal has a total of 367 co-authors. Here are the top co-authors by number of shared publications:
- Malgorzata Anna Zal
Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA
51 shared publications - Michael Andreeff
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
51 shared publications - Aristotelis Tsirigos
Department of Pathology, New York University Grossman School of Medicine, New York, USA
50 shared publications - Audrey Lasry
New York University 3 New York
50 shared publications - Bettina Nadorp
Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, USA
50 shared publications - Bing Z. Carter
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
50 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplemental Figure S1 shows the integration of CRISPR/Cas9 loss-of-function screens to identify dependencies and liabilities in BH3-mimetics treatments. Supplemental Figure S2 demonstrates that increased mitochondria-ER interactions contribute to BH3-mimetics resistance. Supplemental Figure S3 shows that mitophagy affects the responsiveness of AML cells to BH3-mimetics. Supplemental Figure S4 reveals that enhanced autophagic clearance of mitochondria as a mechanism of resistance to BH3-mimetics in AML. Supplemental Figure S5 exhibits the synergism between BH3-mimetics and macroautophagy inhibition in human AML. Supplemental Figure S6 shows that deletion of MFN2 or MARCH5 sensitizes AML cells to BH3-mimetics. Supplemental Figure S7 displays that targeting of MFN2 or MARCH5 impairs the process of mitophagy.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplemental Figure S1 shows the integration of CRISPR/Cas9 loss-of-function screens to identify dependencies and liabilities in BH3-mimetics treatments. Supplemental Figure S2 demonstrates that increased mitochondria-ER interactions contribute to BH3-mimetics resistance. Supplemental Figure S3 shows that mitophagy affects the responsiveness of AML cells to BH3-mimetics. Supplemental Figure S4 reveals that enhanced autophagic clearance of mitochondria as a mechanism of resistance to BH3-mimetics in AML. Supplemental Figure S5 exhibits the synergism between BH3-mimetics and macroautophagy inhibition in human AML. Supplemental Figure S6 shows that deletion of MFN2 or MARCH5 sensitizes AML cells to BH3-mimetics. Supplemental Figure S7 displays that targeting of MFN2 or MARCH5 impairs the process of mitophagy.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table 1 shows the results of our CRISPRi screens.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table 1 shows the results of our CRISPRi screens.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S4 shows autophagy related genes and their ranking in NMF analysis of scRNAseq data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S4 shows autophagy related genes and their ranking in NMF analysis of scRNAseq data.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S3 shows the information of the AML patient samples used in this study.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S3 shows the information of the AML patient samples used in this study.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Methods, Tables, and References
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Methods, Tables, and References
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S2 shows the correlation score of MFN2 expression with the ex vivo drug response (IC50, BeatAML data).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S2 shows the correlation score of MFN2 expression with the ex vivo drug response (IC50, BeatAML data).
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S5 shows sgRNA, primers, shRNA sequences used in this study.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Supplementary Table S5 shows sgRNA, primers, shRNA sequences used in this study.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-7 from Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Supplemental Figure S1 shows the integration of CRISPR/Cas9 loss-of-function screens to identify dependencies and liabilities in BH3-mimetics treatments. Supplemental Figure S2 demonstrates that increased mitochondria-ER interactions contribute to BH3-mimetics resistance. Supplemental Figure S3 shows that mitophagy affects the responsiveness of AML cells to BH3-mimetics. Supplemental Figure S4 reveals that enhanced autophagic clearance of mitochondria as a mechanism of resistance to BH3-mimetics in AML. Supplemental Figure S5 exhibits the synergism between BH3-mimetics and macroautophagy inhibition in human AML. Supplemental Figure S6 shows that deletion of MFN2 or MARCH5 sensitizes AML cells to BH3-mimetics. Supplemental Figure S7 displays that targeting of MFN2 or MARCH5 impairs the process of mitophagy.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-7 from Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Supplemental Figure S1 shows the integration of CRISPR/Cas9 loss-of-function screens to identify dependencies and liabilities in BH3-mimetics treatments. Supplemental Figure S2 demonstrates that increased mitochondria-ER interactions contribute to BH3-mimetics resistance. Supplemental Figure S3 shows that mitophagy affects the responsiveness of AML cells to BH3-mimetics. Supplemental Figure S4 reveals that enhanced autophagic clearance of mitochondria as a mechanism of resistance to BH3-mimetics in AML. Supplemental Figure S5 exhibits the synergism between BH3-mimetics and macroautophagy inhibition in human AML. Supplemental Figure S6 shows that deletion of MFN2 or MARCH5 sensitizes AML cells to BH3-mimetics. Supplemental Figure S7 displays that targeting of MFN2 or MARCH5 impairs the process of mitophagy.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Supplementary Methods, Tables, and References
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Supplementary Methods, Tables, and References
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Supplementary Table S4 shows autophagy related genes and their ranking in NMF analysis of scRNAseq data.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Supplementary Table S4 shows autophagy related genes and their ranking in NMF analysis of scRNAseq data.